Vivaldis Prolivet Tablets for Dogs & Cats | Hepatoprotective Liver Support | Silymarin + Oxomet + Vitamin E | Bottle of 10 Tablets

For use in dogs and cats. Administer as directed by a veterinarian. Keep out of reach of children. Store in a cool, dry place away from direct sunlight.

Vivaldis Prolivet Tablets for Dogs & Cats (Bottle of 10 Tablets)

Vivaldis Prolivet is a veterinary hepatoprotective dietary supplement tablet for dogs and cats, formulated to support and maintain optimal liver function. Prolivet combines Oxomet (a bioactive product derived from the fermentation of Saccharomyces cerevisiae), Siliphos (Silybum marianum extract bound to Phosphatidylcholine — enhanced-bioavailability Silymarin), and Vitamin E to deliver multi-mechanism hepatoprotection. Indicated for use in hepatic insufficiency, chronic liver disease, toxic hepatopathy, post-drug hepatic stress, and as a daily hepatoprotective supplement in breeds predisposed to liver disease. Available in two size-based dosing variants: Upto 15kg and Above 15kg.

Composition (per tablet)

• Oxomet — Product obtained from the fermentation of S. cerevisiae: 210 mg
• Sodium pyrophosphate
• Yeast
• Lupine protein meal
• Mono and diglycerides of fatty acids, sunflower oil, magnesium stearate (excipients)
• Vitamin E (3a700): 21.9 mg
• Siliphos (Silybum marianum — Phosphatidylcholine / lecithin complex): 35 mg

Key Ingredients & Mechanisms of Action

• Oxomet — S. cerevisiae fermentation bioactive (210 mg): Oxomet is a proprietary bioactive fraction derived from controlled fermentation of Saccharomyces cerevisiae (baker’s/brewer’s yeast); the S. cerevisiae fermentation process yields a complex mixture of nucleotides (adenine, guanine, cytosine, uracil — free nucleotides and nucleosides), glutathione precursors (glutamylcysteine peptides), S-adenosylmethionine (SAMe) precursor activity (via methionine and adenosine supply), and beta-glucans; hepatoprotective mechanisms: (1) nucleotide supply — hepatocytes have high nucleotide turnover due to continuous protein synthesis, detoxification reactions (cytochrome P450 CYP2E1, CYP3A4), and urea cycle activity; dietary nucleotide supplementation supports hepatocyte regeneration by providing purines and pyrimidines for DNA/RNA synthesis in proliferating hepatocytes after toxic injury; (2) glutathione (GSH) regeneration support — oxidative stress (from hepatotoxins, xenobiotic metabolism, inflammatory cytokines) depletes hepatocellular glutathione (GSH); Oxomet’s glutamylcysteine peptide content provides a direct precursor pool for GSH resynthesis via glutathione synthetase, maintaining the GSH/GSSG redox ratio; (3) SAMe precursor activity — SAMe is the primary methyl donor for transmethylation reactions in the liver; SAMe supports membrane phosphatidylcholine synthesis (critical for hepatocyte membrane integrity and VLDL lipoprotein assembly — preventing hepatic fat accumulation), cysteine and GSH synthesis (via the transsulfuration pathway: SAMe → cystathionine → cysteine → GSH), and taurine synthesis (bile acid conjugation — taurocholate formation); SAMe also supports polyamine synthesis (spermine, spermidine — hepatocyte proliferation) via decarboxylated SAMe; SAMe deficiency is documented in canine chronic hepatitis and cirrhosis due to reduced hepatic methionine adenosyltransferase (MAT1A) activity; (4) beta-glucan immunomodulation — yeast-derived β-1,3/1,6-glucans modulate hepatic Kupffer cell (liver macrophage) activity via Dectin-1/CR3 signalling, supporting balanced hepatic innate immune responses and reducing LPS-driven inflammatory activation (important in enterohepatic inflammation contributing to chronic hepatitis)
• Siliphos — Silybum marianum (Milk Thistle) × Phosphatidylcholine complex (35 mg): Siliphos is a phytosome complex of Silymarin (the flavonolignan mixture from Silybum marianum seed extract, principally Silybin A and B, Silychristin, Silydianin, Isosilybin A and B) bound to Phosphatidylcholine (PC, lecithin); the PC complexation (phytosome technology) dramatically increases oral bioavailability of silybin — silybin-PC complex (Siliphos) achieves 4–10× higher plasma silybin AUC vs. unconjugated silymarin extract in dogs (confirmed in pharmacokinetic studies); mechanisms of Silymarin/Silybin hepatoprotection: (1) antioxidant — Silybin is a potent iron chelator (Fe2+/Fe3+ chelation reduces Fenton reaction-derived hydroxyl radical ·OH generation) and direct free radical scavenger (donates H· to lipid peroxyl radicals, terminating lipid peroxidation chain reactions in hepatocyte membranes); Silybin upregulates glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity via Nrf2/ARE pathway activation (Nrf2 → Keap1 dissociation → nuclear translocation → antioxidant response element activation → HO-1, NQO1, GCL, GPx, SOD upregulation); (2) anti-inflammatory — Silybin inhibits NF-κB (p65/p50 nuclear translocation blockade — reduces TNF-α, IL-1β, IL-6, MCP-1 hepatic cytokine expression); inhibits 5-lipoxygenase (5-LOX — reduces LTB4 leukotriene synthesis in hepatic Kupffer cells); (3) anti-fibrotic — Silybin inhibits hepatic stellate cell (HSC) activation (TGF-β1-driven α-SMA expression, collagen type I/III deposition — reduced by Silybin via SMAD2/3 phosphorylation inhibition and SMAD7 upregulation); reduces TIMP-1 (tissue inhibitor of metalloproteinase) expression while supporting MMP activity, promoting remodelling of existing hepatic collagen; (4) membrane stabilisation — Silybin intercalates into hepatocyte phospholipid bilayers, reducing membrane fluidity-dependent permeabilisation by hepatotoxins (CCl4, acetaminophen/paracetamol, Amanita phalloides amatoxins, mycotoxins, NSAIDs); this physically restricts toxin transmembrane entry into hepatocytes; (5) nuclear receptor modulation — Silybin is a liver X receptor (LXR) and farnesoid X receptor (FXR) ligand; FXR activation reduces CYP7A1 (cholesterol 7α-hydroxylase) expression, reducing bile acid synthesis flux and protecting against bile acid-induced hepatocyte apoptosis in cholestatic liver disease; (6) Phosphatidylcholine contribution — PC directly supports hepatocyte membrane phospholipid repair (PC is the dominant phospholipid in the hepatocyte outer leaflet); PC also facilitates VLDL assembly and triglyceride export from hepatocytes (prevents hepatic lipid accumulation/steatosis); PC activates PPARα (peroxisome proliferator-activated receptor alpha — fatty acid beta-oxidation — reduces hepatocellular triglyceride content)
• Vitamin E (3a700) — 21.9 mg: Vitamin E (α-tocopherol, here as the feed additive form 3a700 = all-rac-alpha-tocopheryl acetate) is the primary lipid-soluble chain-breaking antioxidant in biological membranes; α-tocopherol terminates lipid peroxidation chain reactions in hepatocyte phospholipid bilayers by donating a hydrogen atom to lipid peroxyl radicals (LOO· + α-T-OH → LOOH + α-T-O·); α-tocopheroxyl radical (α-T-O·) is then regenerated (reduced) by ascorbate (Vitamin C) and GSH-dependent ascorbate regeneration systems; Vitamin E deficiency markedly worsens hepatic oxidative damage in dogs with chronic hepatitis and copper-associated hepatopathy; Vitamin E supplementation is recommended as standard of care in canine chronic hepatitis guidelines (WSAVA Liver Disease Standards)
• Lupine protein meal: Lupinus sp. seed protein concentrate; provides branched-chain amino acids (BCAA — leucine, isoleucine, valine) and aromatic amino acid-depleted protein for hepatic encephalopathy risk reduction (BCAA:AAA ratio improvement); also provides arginine, methionine, and cysteine as precursors for urea cycle, GSH synthesis, and taurine synthesis

Therapeutic Class

• Veterinary hepatoprotective dietary supplement — Silymarin (Siliphos phytosome) + Oxomet (S. cerevisiae fermentation) + Vitamin E — antioxidant, anti-inflammatory, anti-fibrotic, membrane stabilising, SAMe/GSH precursor — chronic liver disease, toxic hepatopathy, hepatic insufficiency — dogs and cats

Indications

• Chronic hepatitis and hepatic insufficiency in dogs and cats
• Toxic hepatopathy — drug-induced (NSAIDs, corticosteroids, phenobarbital, azathioprine, ketoconazole), mycotoxin, or chemical hepatotoxin exposure
• Hepatic lipidosis (fatty liver disease) in cats
• Copper-associated hepatopathy in dogs (Bedlington Terrier, Labrador Retriever, West Highland White Terrier, Dobermann)
• Cholestatic liver disease
• Post-anaesthetic and post-surgical hepatoprotection
• Chronic phenobarbital or potassium bromide antiepileptic therapy hepatoprotection
• Liver enzyme elevation (ALT, AST, ALP) maintenance support
• Daily hepatoprotective supplementation in predisposed breeds

Dosage & Administration

• Upto 15kg variant — for dogs and cats up to 15kg body weight
• Above 15kg variant — for dogs above 15kg body weight
• Confirm daily dose and duration from product label or as directed by a veterinarian
• 10 tablets per bottle; administer orally with or without food

Safety Information

• Generally very well tolerated; mild GI upset (soft stools, mild nausea) possible at initiation
• Silymarin has an excellent safety profile in dogs and cats at recommended doses
• Store in a cool, dry place; keep out of reach of children